NMNubia Muñoz

Nubia Muñoz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nubia Muñoz has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative distribution of HPV genotypes in penile and vulvar squamous cell carcinomas with basaloid or warty (condylomatous) features

    by Diego F. Sánchez, María José Fernández-Nestosa, Sofía Cañete-Portillo, Antonella Lobatti, Leticia Santacruz, Belén Lloveras, Jaume Ordi, Laia Allemany, Nubia Muñoz, Sylvia de Sanjosé, et al.

  • Open Access

    Comparación de subtipos histológicos y genotipos del virus del papiloma humano (VPH) en la neoplasia intraepitelial del pene (PEIN) con y sin carcinoma escamoso invasivo: un estudio de 76 lesiones en 43 pacientes utilizando microdisección por captura láser y PCR

    by María José Fernández-Nestosa, Diego F. Sánchez, Leticia N. Santacruz, Nuria Guimerà, Elsa F. Velázquez, Ingrid Rodríguez, Nubia Muñoz, Antonio L. Cubilla

    La neoplasia intraepitelial de pene (PeIN) y el carcinoma de pene invasivo presentan un perfil bimodal: VPH-independiente y VPH-asociado. La PeIN puede ocurrir como lesión aislada o asociada a carcinoma invasivo. Este estudio compara los subtipos histológicos y los genotipos de VPH entre ambos grupos. Se evaluaron 40 lesiones de PeIN aisladas (17 pacientes) y 36 lesiones de PeIN asociadas a carcinoma invasivo (26 pacientes). Las lesiones se clasificaron como VPH-independientes (diferenciada), VPH-asociadas (basaloide, warty-basaloide, warty) o mixtas. Se realizó microdisección por captura láser (LCM) y genotipificación con el sistema SPF-10/DEIA/LiPA25. La PeIN diferenciada fue significativamente más frecuente en los casos con carcinoma invasivo, mientras que la PeIN VPH-asociada predominó en las lesiones aisladas Se detectó mayor diversidad de genotipos VPH en PeIN aislada (15 vs 6 genotipos). Genotipos exclusivos de PeIN aislada incluyeron VPH 30, 33, 35, 39, 44, 58, 66, 73, 84, 87, 51 y 59; los exclusivos de PeIN con carcinoma invasivo fueron VPH 11, 18 y 74. VPH 16, 52 y 56 fueron comunes a ambos grupos. La falta de correspondencia de los subtipos histológicos y genotipos detectados entre las PeIN aisladas y las asociadas a carcinoma sugiere que varias lesiones PeIN aisladas no progresan a carcinoma invasivo.

  • Pelayo Correa, MD, FAACR: In Memoriam (1927–2025)

    by M. Constanza Camargo, M. Blanca Piazuelo, Meira Epplein, Karen J. Goodman, Julie Parsonnet, Nubia Muñoz

  • In memoriam: Pelayo Correa, MD (1927–2025)

    by Luis Eduardo Bravo, M Constanza Camargo, M Blanca Piazuelo, Nubia Muñoz

  • Open Access

    In Memoriam: Pelayo Correa (1927–2025)

    by Luis Eduardo Bravo, M. Constanza Camargo, Maria Blanca Piazuelo, Nubia Muñoz

    Pelayo Correa, born in Sonsón, Antioquia, in 1927, was one of the most influential figures in cancer epidemiology and pathology in Latin America and worldwide. His work transformed the understanding of gastric carcinogenesis and gave rise to one of the most solid and longstanding population-based registries on the continent. His scientific life - defined by rigor, curiosity, and public service - leaves an enduring legacy for generations of researchers. Professor Correa graduated as a physician from the University of Antioquia in 1949, where he completed his thesis on cancer statistics in the department —pioneering work that sparked his lifelong interest in differences in cancer risk across populations. This early study took him to Emory University in the United States, where he trained as a pathologist and solidified his etiologic vocation: to understand the causes of disease, not only its morphological expression. After completing his training, he returned to Colombia and joined the Universidad del Valle. During a 1961 congress, his presentation on cancer patterns in Cali drew the attention of Dr. Harold Stewart of the National Cancer Institute (NCI), who shared the data with Dr. William Haenszel. From that exchange, Dr. Haenszel traveled to Cali and, together with Professor Correa, helped establish the Cali Population-Based Cancer Registry (RPCC), the first in Latin America and today one of the oldest in the world. Dr. Haenszel also served as his mentor in epidemiology, contributing to the design and conduct of the investigations that followed in subsequent decades, aimed at clarifying the determinants of gastric cancer. The strength of the Cali Registry became evident early on. The RPCC publication in the Journal of the National Cancer Institute in April 1966 coincided with the release of the first volume of Cancer Incidence in Five Continents(January 1966), which included RPCC data. This convergence placed the Cali registry within the foundational landmarks of global cancer surveillance. At a time when the world was beginning to standardize comparative incidence measurement, Professor Correa’s work provided rigorous data from Latin America, demonstrating that his epidemiological vision was not only aligned with global developments but contributed to them from the outset.

  • Open Access

    COVID-19 in Latin America: a first glance to the mortality

    by Nubia Muñoz

    Aun no conocemos cual será la mortalidad por el virus Covid-19 o SARS-CoV-2 en América Latina porque la epidemia esta aun active y no sabemos cuándo terminará. La curva de infecciones nuevas y de muerte aun no alcanzado el pico, (Figura 1), y además conocemos muy poco de la epidemiologia de este nuevo virus. La diaria letanía del número de infectados por el virus SARS-CoV-2 o Covid-19, del número de hospitalizados y de muertos, orienta las autoridades sanitarias a planear servicios y a los políticos a calibrar el grado de confinamiento necesario para controlar la transmisión del virus, pero dice poco sobre la magnitud del problema si no lo relacionamos con la población en riesgo. Al final de la pandemia podremos estimar tasas de mortalidad estandarizadas por edad para los diferentes países, pero por el momento con las tasas crudas de mortalidad podemos dar una primera mirada, y vemos que el virus ha atacado a los países Latinoamericanos con intensidad variable. La tabla 1 resume las grandes diferencias en las tasas crudas de mortalidad por 100.000 habitantes en 15 países de la región de marzo a mayo 2020. Ecuador, Brasil y Perú tienen las mayores tasas de mortalidad, seguidos por Panamá. México, Chile y Bolivia, mientras que Colombia, Argentina, Cuba, Uruguay, Paraguay y Costa Rica tienen las menores. Estas tasas son inferiores a las estimadas en los países europeos: Bélgica (82.6), España (58.0), Reino Unido (57.5), Italia (55.0), Francia (42.9), Suecia (42.7), y en US (31.4). (Johns Hopkins CSSE, 30 de mayo 2020). (Figura 1).Hay que tener en cuenta que las tasas menciondas son crudas, y que parte de las diferencia puede deberse a que los países europeos tienen una mayor proporción de población de adultos mayores, que son los que tienen tasas de mortalidad por Covid-19 mas elevadas. It is too early to know which will be the final death toll from the Covid-19 or SARS-CoV-2 virus epidemy in Latin America since the epidemy is still active and we will not know when it will end. The curve for new infections and deaths has not reached yet a peak (Figure 1). In addition, we know little about the epidemiology of this new virus. The daily litany of the number of people infected with the number of admissions to hospitals and intensive care units and the number of deaths guides health authorities to plan health services and politicians to gauge the degree of confinement necessary to control the transmission of the virus, but it says little about the magnitude of the problem if we do not relate it to the population at risk. At the end of the pandemic, we will be able to estimate age-standardized death rates for the different countries, but until then the crude death rates will provide a first glance or snapshot of the death toll and impact of the pandemic from March to May 2020. These rates are well below those estimated in other countries in Europe and North America: Belgium (82.6), Spain (58.0), the United Kingdom (57.5), Italy (55.0), France (42.9), Sweden (41.4), and the US (30.7). (Johns Hopkins CSSE, May 30, 2020). However, in the European countries and the US the number of deaths has reached a peak, while this is not the case in Latin American countries. (Figure 1). It should be taken into account that the above rates are crude and therefore, some of the differences could be due to the fact that European countries have a larger proportion of the population over 70 years of age in whom higher mortality rates have been reported.


  • Open Access

    Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection

    by Iacopo Baussano, Mireia Diaz, Stephen Tully, Nubia Muñoz, Silvia de Sanjosé, F. Xavier Bosch, Silvia Franceschi


  • Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions

    by Beatriz Serrano, Silvia de Sanjosé, Sara Tous, Beatriz Quiros, Nubia Muñoz, Xavier Bosch, Laia Alemany


  • Open Access

    Hepatitis C virus seroprevalence in the general female population from 8 countries

    by Paloma Quesada, Denise Whitby, Yolanda Benavente, Wendell Miley, Nazzarena Labo, Saibua Chichareon, Nguyen Trong, Hai-Rim Shin, Pham Thi Hoang Anh, Jaiyeola Thomas, et al.


  • Open Access

    Epidemiology of cervical cancer in Colombia

    by Nubia Muñoz, Luis Eduardo Bravo

    Worldwide, cervical cancer is the third most common cancer in women, and the first or second most common in developing countries. Cervical cancer remains in Colombia the first cause of cancer mortality and the se­cond cause of cancer incidence among women, despite the existence of screening programs during the last 3 decades. Bucaramanga, Manizales and Cali reported rates around 20 per 100,000 and Pasto 27 per 100,000. The Cali cancer registry has reported a progressive decrease in the age standardized incidence and mortality rates of cervical cancer over the past 40 years. Reasons for the decline in incidence and mortality of cervical cancer are multiple and probably include: improvement in socio-economic conditions, decrease in parity rates and some effect of screening programs. Human papilloma Virus is the main cause of cervical cancer, HPV natural history studies have now revealed that HPVs are the commonest of the sexually transmitted infections in most populations. Most HPV expo­sures result in spontaneous clearance without clinical manifestations and only a small fraction of the infected persons, known as chronic or persistent carriers, will retain the virus and progress to precancerous and cancer. HPV 16 and 18 account for 70% of cervical cancer and the 8 most common types. (HPV 16, 18, 45, 33, 31, 52, 58 and 35) account for about 90% of cervical cancer. Case-control studies also allowed the identification of the following cofactors that acting together with HPV increase the risk of progression from HPV persistent infection to cervical cancer: tobacco, high parity, long term use of oral contraceptives and past infections with herpes simplex type 2 and Chlamydia trachomatis. The demonstration that infection with certain types of human papillomavirus (HPV) is not only the main cause but also a necessary cause of cervical cancer has led to great advances in the prevention of this disease on two fronts: (i) Primary prevention by the use of prophylactic HPV vaccines; and (ii) secondary prevention by increasing the accuracy of cervical cancer screening.